So far, five biosimilars that reference Eylea 2 mg have been approved by the FDA. Alvotech/Teva expect to regulatory approval ...

Older patients with diabetic macular edema have a weaker response to anti-VEGF treatment, according to a presentation at ...

Ixo-vec is a potential best-in-class one-time gene therapy designed to deliver long-term efficacy, reduce the burden of frequent anti-VEGF and ...

Adverum Biotechnologies (ADVM) announced the initiation of the ARTEMIS Phase 3 study. This pivotal trial is designed to evaluate the efficacy ...

FYB203, a biosimilar to aflibercept, received UK MHRA approval for multiple retinal conditions and will be marketed as ...

Alvotech and Teva Pharmaceuticals announced the US Food and Drug Administration (FDA) has accepted for review a Biologics ...

Celltrion expands its reach in Europe, securing marketing authorization from the European Commission (EC) for its denosumab ...

In the randomized, sham-controlled ARTEMIS study, patients will receive either a dose of ixo-vec or a standard care regimen of anti-VEGF Eylea.

February brought policy updates and several biosimilar approvals, including the first FDA approval for an insulin aspart biosimilar.

In addition to AVT06, which is a biosimilar candidate for Eylea ® (aflibercept) 2 mg, Alvotech is currently also developing AVT29, a biosimilar candidate for Eylea ® HD (aflibercept) 8 mg. Teva also ...

Celltrion today announced that the European Commission (EC) has granted marketing authorization for three products across two biosimilars: Eydenzelt® ...